Asia-Pacific Colorectal Cancer Therapeutics in Markets to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
125
Asia-Pacific Colorectal Cancer Therapeutics in Markets to 2023: Market will be valued at $7.9 billion in 2023, growing from $4.7 billion in 2016

Dublin, Dec. 07, 2017 (GLOBE NEWSWIRE) -- The "Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" report has been added to Research and Markets' offering.

The report Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market analyzes the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. Furthermore, this report helps to understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.

China has the most newly diagnosed CRC cases in Asia-Pacific (APAC). In 2011, there were 310,200 incident cases in the country and this rose to 376,300 in 2015. CRC is the most common malignancy among Chinese males, with an estimated incidence of 215,700 men and 160,600 women in 2015. Mortality in 2011 stood at 149,700, and in 2015 rose to 191,000 (Chen et al., 2016). In Japan, the incidence and mortality of CRC have substantially increased. In 2012, the incidence of colon and rectum cancer in Japan was 87,800 and 46,800 cases respectively, and mortality was 32,200 and 15,100 cases (NCC, 2016a). CRC is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms among women, and the third largest among men (Watanabe et al., 2015). In 2016, there were an estimated 147,200 new CRC cases and 51,600 deaths in the country (NCC, 2016b). In Australia, the five-year survival rate increased from 50% between 1984 and 1988 to 69% between 2009 and 2013. Improvement in survival from CRC may be due to earlier diagnosis and the availability of better treatment options (AGCA, 2017). The incidence of CRC is still several folds lower in India than in most developing and developed countries (Mallath, 2014). However, the country has witnessed a steady increase in numbers in line with its increasing urbanization. Companies mentioned in this report:

  • Merck & Co.
  • Roche
  • Sumitomo Dainippon Pharma
  • Array BioPharma
  • AB Science
  • Hutchison MediPharma
  • Jiangsu Chia-Tai Tianqing
  • Suzhou Zelgen Biopharmaceuticals

Scope The CRC Asia-Pacific market will be valued at $7.9 billion in 2023, growing from $4.7 billion in 2016 at a CAGR of 7.9%.

  • How will immune checkpoint inhibitors such as Keytruda and Tecentriq contribute to growth?
  • What effect will patent expirations of currently branded therapies have on market value?

The CRC pipeline is large and diverse, with an strong presence of mAbs and targeted therapies.

  • What are the common targets and mechanisms of action of pipeline therapies?
  • Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAF-mutant CRC patients?
  • What implications will the increased focus on targeted therapies have on the future of CRC treatment?

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

  • How have the late-stage therapies performed in clinical trials?
  • How would the approval of encorafenib plus binimetinib to treat BRAF-mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.

  • How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
  • How could changes in risk factors such as population age, obesity and lifestyle influence the market?

Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under $10m to over $3 billion.

  • How do deal frequency and value compare between target families and molecule types?
  • What were the terms and conditions of key licensing deals?

Key Topics Covered:

1 Table of Contents 2 Introduction 2.1 Disease Introduction 2.2 Epidemiology 2.3 Symptoms 2.4 Etiology and Pathophysiology 2.4.1 Etiology 2.4.2 Pathophysiology 2.4.3 Biomarkers/Targets of Interest 2.5 Diagnosis 2.5.1 Digital Rectal Examination 2.5.2 Fecal Occult Blood Test 2.5.3 Flexible Sigmoidoscopy 2.5.4 Colonoscopy 2.5.5 Virtual Colonoscopy 2.5.6 Double Contrast Barium Enema 2.6 Disease Stages 2.7 Prognosis 2.8 Treatment Guidelines and Options 2.8.1 Surgery and Radiation Therapy 2.8.2 Chemotherapy 2.8.3 Targeted Therapies 2.8.4 Resistance to Pharmacological Therapies 2.8.5 Treatment Algorithm 3 Marketed Products 3.1 Overview 3.2 Chemotherapies 3.2.1 Lonsurf (Trifluridine plus Tipiracil) - Taiho Pharma 3.2.2 TS-1 (Tegafur plus Gimeracil plus Oteracil) - Taiho Pharma 3.2.3 UFT (tegafur plus uracil) - Merck KGaA 3.3 Epidermal Growth Factor Receptor Targeted Therapies 3.3.1 Erbitux (cetuximab) - Eli Lilly/Merck KGaA 3.3.2 Vectibix (panitumumab) - Amgen/Takeda 3.4 Anti-angiogenesis Therapies 3.4.1 Avastin (bevacizumab) - Roche 3.4.2 Cyramza (ramucirumab) - Eli Lilly 3.4.3 Zaltrap (Ziv-Aflibercept) - Sanofi/Regeneron 3.5 Kinase Inhibitors 3.5.1 Stivarga (regorafenib) - Bayer/Onyx 3.6 Comparative Efficacy and Safety of Marketed Products 4 Pipeline Analysis 4.1 Overview 4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 4.3 Pipeline by Molecular Target 4.4 Promising Pipeline Candidates 4.4.1 Keytruda (pembrolizumab) - Merck & Co. 4.4.2 Tecentriq plus Cotellic (Atezolizumab plus cobimetinib) - Roche 4.4.3 Napabucasin (BBI-608) - Sumitomo Dainippon Pharma 4.4.4 Encorafenib plus binimetinib (LGX-818/MEK-162) - Array BioPharma 4.4.5 Masitinib - AB Science 4.4.6 Fruquintinib (HMPL-013) - Hutchison MediPharma 4.4.7 Famitinib (SHR-1020) - Jiangsu Hengrui Medicine 4.4.8 Anlotinib (AL-3818) - Jiangsu Chia-Tai Tianqing 4.4.9 Donafenib (CM-4307) - Suzhou Zelgen Biopharmaceuticals 4.5 Comparative Efficacy and Safety of Pipeline Products 4.6 Product Competitiveness Framework 5 Clinical Trial Analysis 5.1 Failure Rate 5.1.1 Overall Failure Rate 5.1.2 Failure Rate by Phase and Molecule Type 5.1.3 Failure Rate by Phase and Molecular Target 5.2 Clinical Trial Size 5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development 5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development 5.2.3 Patient Enrollment per Trial by Molecule Type and Stage of Development 5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development 5.3 Clinical Trial Duration 5.3.1 Trial Duration by Molecule Type and Stage of Development 5.3.2 Trial Duration by Molecular Target and Stage of Development 5.4 Summary of Clinical Trial Metrics 6 Multi-scenario Forecast 6.1 Overview 6.2 Asia-Pacific Market 6.3 India 6.3.1 Treatment Usage Patterns 6.3.2 Annual Cost of Therapy 6.3.3 Market Size 6.4 China 6.4.1 Treatment Usage Patterns 6.4.2 Annual Cost of Therapy 6.4.3 Market Size 6.5 Australia 6.5.1 Treatment Usage Patterns 6.5.2 Annual Cost of Therapy 6.5.3 Market Size 6.6 South Korea 6.6.1 Treatment Usage Patterns 6.6.2 Annual Cost of Therapy 6.6.3 Market Size 6.7 Japan 6.7.1 Treatment Usage Patterns 6.7.2 Annual Cost of Therapy 6.7.3 Market Size 7 Drivers and Barriers 7.1 Drivers 7.1.1 Increasing Elderly Population and Incidence of CRC 7.1.2 Increasing Screening Programs and Approval of New Screening Tests for CRC to Drive Early Diagnosis Rate 7.1.3 Increase in Mutation Testing to Drive Market Growth 7.1.4 Availability of Novel First-, Second- and third-Line Therapy Options in Pipeline 7.1.5 Diversified Healthcare Reform to Boost Market Growth 7.1.6 Diversified Health Insurance System to Help Nurture Growth 7.2 Barriers 7.2.1 Patent Expiration of Branded Therapies to Affect CRC Market Growth 7.2.2 High Prices of Therapeutics to Slow Down Market Growth 7.2.3 Limited Incorporation of Immunotherapies in the CRC Treatment Algorithm 7.2.4 Lack of Development of Neoadjuvant and Adjuvant Pipeline Products 7.2.5 Lack of Reimbursement and Penetration of Generic Drugs to Hinder Market Growth in China and India 7.2.6 Drug Pricing Reforms 8 Deals and Strategic Consolidations 8.1 Licensing Deals 8.1.1 Deals by Region and Value 8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 8.1.4 Key Licensing Deals 8.2 Co-development Deals 8.2.1 Deals by Region and Value 8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 8.2.4 Key Co-development Deals 9 Appendix

Companies Mentioned

  • AB Science
  • Amgen
  • Array BioPharma
  • Bayer
  • Eli Lilly
  • Hutchison MediPharma
  • Jiangsu Chia-Tai Tianqing
  • Merck & Co.
  • Onyx
  • Regeneron
  • Roche
  • Sanofi
  • Sumitomo Dainippon Pharma
  • Suzhou Zelgen Biopharmaceuticals
  • Taiho Pharma
  • Takeda

For more information about this report visit https://www.researchandmarkets.com/research/9...tal_cancer

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Genomics, Colon Cancer Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 225

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 71

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
Utility Global’s India Steel Move Needs Hard Numbers

Updated Category News Views 114

Steel decarbonization announcements can sound enormous before a single bolt gets tightened. Utility Global says it plans to deploy its first industrial H2Gen project in India with Tata Steel, and that is plainly worth watching. Tata Steel is a serious industrial name, India is a consequential steel market, and any technology that can credibly lower emissions from heavy...

Continue Reading
Paladone Tests LEGO's Everyday Collectibles Pull Abroad

Updated Category News Views 71

A glowing minifigure lamp is not exactly a macroeconomic event, but licensed merchandise has a funny way of revealing where household spending still has a pulse. Paladone Products has put its first LEGO-branded collection into stores, a modest-looking launch with some real retail logic behind it. This is not a grand toy-box bet on one blockbuster item. It is a spread of...

Continue Reading
Texas Restaurants Get a New Read on Customer Demand

Updated Category News Views 88

Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...

Continue Reading
Tonum and Euvita Link Supplements to Personalized Care

Updated Category News Views 8

Muscle loss has become the awkward footnote in the GLP-1 weight-loss boom, and Tonum Health is trying to put that concern nearer the center of the care conversation. Its newly announced partnership with euvita health places Tonum's supplements and functional nutrition products inside a physician-led platform built around biomarker testing, hormone and peptide therapy,...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 83

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
Qonto's Banking License Raises the Stakes in Europe

Updated Category News Views 70

A regulatory stamp can look dull on paper, yet this one changes the machinery underneath Qonto. The Paris-based finance platform has received a Credit Institution license from France's ACPR and the European Central Bank, giving it a route to offer broader lending and savings products directly to small and midsize businesses across Europe. That is a serious corporate...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 296

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
APEC's Shared-Prosperity Message Needs More Detail

Updated Category News Views 20

Geese make handsome symbols, but markets cannot underwrite a metaphor. The Nov. 18, 2026 report from Xinhua News Agency looks back to remarks Chinese President Xi Jinping made 12 years ago, when he used swan geese to urge APEC economies toward greater cooperation and a new collective flight. Its present-day message is plainly hopeful: the APEC family is moving across the...

Continue Reading

Top 5 Most Recently Viewed Articles

Therap Services Implements SMS Security Features for Users

Updated Category News Views 172

Enhancing Security and User Control with SMS Features Therap Services is at the forefront of improving data protection in the realm of electronic documentation solutions specifically tailored for the Long-Term Services and Supports (LTSS) and Home and Community-Based Services (HCBS). By recently rolling out SMS-based password reset and two-factor authentication (2FA)...

Continue Reading
Understanding Stakeholder Disclosures in Student Property Sector

Updated Category News Views 127

Key Insights into Stakeholder Disclosure Regulations Stakeholder disclosures play a crucial role in maintaining transparency in the market, particularly in industries like real estate and student accommodations. Understanding these requirements is essential for investors and companies alike. This discussion focuses on the significance of disclosures concerning relevant...

Continue Reading
VestGen Wealth Partners Expands Leadership for Enhanced Services

Updated Category News Views 130

VestGen Expands Leadership Team to Elevate Client Services In a strategic move aimed at enhancing its operations and service offerings, VestGen Wealth Partners, LLC has announced a significant expansion of its leadership team. This includes the appointment of Rob Bondiman as the National Head of Advisors and Matt LaLonde as the inaugural Director of Insurance, heading...

Continue Reading
Toll Brothers Launches Stunning New Townhome Community

Updated Category News Views 304

Introducing Toll Brothers at East Cobb Walk Toll Brothers, Inc., renowned for its premium housing, has unveiled its new community, now available for sale. This exciting release presents a rare opportunity for homebuyers to invest in beautiful townhomes within an attractive neighborhood. Luxury Townhomes with Modern Designs The new community, Toll Brothers at East Cobb...

Continue Reading
Understanding Assura Plc's Recent Public Disclosure

Updated Category News Views 129

Public Disclosure Overview Understanding public disclosures is crucial for investors and stakeholders in the financial market. In this article, we will explore Assura Plc's latest public disclosure under Rule 8.3 of the Takeover Code. The company revealed significant information about interests that represent over 1% of certain securities. These disclosures aim to provide...

Continue Reading